ArticleFrontiers in neuroscience2026
Editorial: Biofluid biomarkers for the diagnosis of neurodegenerative diseases: current status.
Boris Decourt, Michelle M Mielke, Paul Desmond Slowey, Marwan N Sabbagh
Abstract readEditorial
In one paragraphArticle in Frontiers in neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
4 authors.
Boris DecourtDepartment of Pharmacology and Neuroscience, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Michelle M MielkeDepartment of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, United States.
Paul Desmond SloweyOasis Diagnostics Corporation, Vancouver, WA, United States.
Marwan N SabbaghAlzheimer's and Memory Disorders Division, Barrow Neurological Institute, Phoenix, AZ, United States.
Funding
Alzheimer Diagnosis in older Adults with Chronic Conditions ADACC NetworkU24AG082930 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Nicole R. Fowler, Thomas K Karikari · 2023 to 2026
$7.3MSex-specific risk factors and trajectories of blood biomarkers for Alzheimer's disease and related dementiasRF1AG079397 · NIA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI MIELKE, MICHELLE M, MURRAY, ANNE M · 2022 to 2024
$4.5MMCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI PatientsR01AG059008 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI DECOURT, BORIS, SABBAGH, MARWAN NOEL · 2018 to 2023
$3.6MStress, Weathering, and Blood-Based Biomarkers of Alzheimer’s Disease: A Longitudinal Study of Low Income, Aging African AmericansRF1AG077386 · NIA · UNIVERSITY OF GEORGIA · PI MIELKE, MICHELLE M, SIMONS, RONALD L · 2022 to 2023
$3.2MRepurposing Siponimod for Alzheimer's DiseaseR01AG073212 · NIA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI Boris Decourt, MARWAN Noel SABBAGH · 2021 to 2026
$2.8M"What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementiasRF1AG069052 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, MIELKE, MICHELLE M · 2021 to 2021
$2.4MNIA NIH HHS R01 AG059008NIA NIH HHS R01 AG073212NIA NIH HHS RF1 AG069052NIA NIH HHS RF1 AG077386NIA NIH HHS RF1 AG079397NIA NIH HHS U24 AG082930
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
biofluidbiomarkerclinical trialcontext of use (COU)measurement platformneurodegenerative diseasestissue matrix
Identifiers
PMID42835159
PMCPMC13635364
What OpenQuestion holds
Textmetadata
Read underepoch 390